Aligos Therapeutics (ALGS) to Release Earnings on Monday

Aligos Therapeutics (NASDAQ:ALGS) is projected to post its quarterly earnings results before the market opens on Monday, March 10th. Analysts expect Aligos Therapeutics to post earnings of ($2.63) per share and revenue of $0.43 million for the quarter.

Aligos Therapeutics Price Performance

ALGS stock opened at $12.94 on Friday. Aligos Therapeutics has a 52-week low of $6.76 and a 52-week high of $46.80. The company has a 50-day moving average of $27.25 and a two-hundred day moving average of $20.53. The stock has a market capitalization of $46.43 million, a price-to-earnings ratio of -0.97 and a beta of 2.52.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).